The findings provide promise of targeted treatment for patients with the disease.

Research uncovers racial bias in oxygen readings during the pandemic, even amongst patients needing ECMO.

Researchers say it’s a sign that more targeted therapies are needed for the vulnerable patient population.

Patients with obesity are especially at risk.

A phase 3 clinical trial finds an anti-inflammatory drug used in rheumatoid arthritis can preserve lung function in patients with systemic sclerosis.

Osteopontin is discovered as the culprit behind these patients’ main cause of death. However, a repurposed immunosuppressive drug may combat the pro-inflammatory protein.